Amgen Inc. Payments of Debt Issuance Costs
Amgen Inc. (AMGN) reported Payments of Debt Issuance Costs of $18.00 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-19.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2015-02-19
- Amgen Inc. payments of debt issuance costs for the quarter ending 2012-12-31 was $0.00, a 100.00% decline year-over-year.
- Amgen Inc. payments of debt issuance costs for the quarter ending 2012-09-30 was $10.00M.
- Amgen Inc. payments of debt issuance costs for the quarter ending 2011-12-31 was $38.00M.
- Amgen Inc. payments of debt issuance costs for the quarter ending 2011-09-30 was $0.00.
- Amgen Inc. payments of debt issuance costs for fiscal 2014 was $18.00M, a 60.87% decline from fiscal 2013.
- Amgen Inc. payments of debt issuance costs for fiscal 2013 was $46.00M, a 84.00% increase from fiscal 2012.
- Amgen Inc. payments of debt issuance costs for fiscal 2012 was $25.00M, a 54.55% decline from fiscal 2011.
- Amgen Inc. payments of debt issuance costs for fiscal 2011 was $55.00M, a 223.53% increase from fiscal 2010.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2014-12-31 | $18.00M 10-K · filed 2015-02-19 | |||
| 2013-12-31 | $46.00M 10-K · filed 2015-02-19 | |||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $10.00M derived: sum of 2 quarters · filed 2015-02-19 | $25.00M 10-K · filed 2015-02-19 | |
| 2012-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $25.00M 10-Q · filed 2012-11-06 | ||
| 2012-06-30 | $15.00M 10-Q · filed 2012-08-08 | |||
| 2011-12-31 | $38.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-24 | $38.00M derived: sum of 2 quarters · filed 2014-02-24 | $55.00M 10-K · filed 2014-02-24 | |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $17.00M 10-Q · filed 2011-11-04 | ||
| 2011-06-30 | $17.00M 10-Q · filed 2011-08-08 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $17.00M 10-K · filed 2013-02-27 | ||
| 2010-09-30 | $17.00M 10-Q · filed 2010-11-08 | |||
| 2009-12-31 | $13.00M 10-K · filed 2012-02-29 | |||
| 2008-12-31 | $6.00M 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |